Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis

Pharmacological Research

Volumn 159, Issue , 2020, Pages

  Zheng, Qiyan ^a,b   Yang, Huisheng ^c   Sun, Luying ^a,b   Wei, Ruojun ^a,b   Fu, Xinwen ^a,b   Wang, Yahui ^a,b   Huang, Yishan ^a,b   Liu, Yu Ning ^a,b   Liu, Wei Jing ^a,b,d  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^d GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Anemia; Chronic kidney disease; Darbepoetin; Epoetin; HIF prolyl hydroxylase inhibitors; Non dialysis

Indexed keywords

DAPRODUSTAT; DESIDUSTAT; ENARODUSTAT; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; MOLIDUSTAT; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROXADUSTAT; VADADUSTAT; ANTIANEMIC AGENT; BIOLOGICAL MARKER; ENZYME INHIBITOR; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE;

ALL CAUSE MORTALITY; ANEMIA; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; META ANALYSIS; MORTALITY RISK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; AGED; BLOOD; COMPLICATION; ENZYMOLOGY; FEMALE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NETWORK META-ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; BIOMARKERS; DARBEPOETIN ALFA; ENZYME INHIBITORS; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MALE; MIDDLE AGED; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85086778132     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2020.105020     Document Type: Review

References (60)

1. Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A.Y., Yang, C.W., Chronic kidney disease: global dimension and perspectives. LANCET 382:9888 (2013), 260–272, 10.1016/S0140-6736(13)60687-X.
2. Coresh, J., Selvin, E., Stevens, L.A., Manzi, J., Kusek, J.W., Eggers, P., Lente, F.V., Levey, A.S., Prevalence of chronic kidney disease in the United States. JAMA 298:17 (2007), 2038–2047, 10.1001/jama.298.17.2038.
3. Muirhead, N., A rationale for an individualized haemoglobin target. Nephrol. Dial. Transplant. 17:90006 (2002), 2–7, 10.1093/ndt/17.suppl_6.2.
4. Regidor, D.L., Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 17:4 (2006), 1181–1191, 10.1681/ASN.2005090997.
5. Collins, A.J., Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol. Dial. Transplant. 18:Suppl 2(6) (2003), i2–i6.
6. Benz, R., Schmidt, R., Kelly, K., Wolfson, M., Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2:2 (2007), 215–221, 10.2215/CJN.02590706.
7. Solomon, S., Uno, H., Lewis, E., Al, E., Erythropoietic response and outcomes in kidney disease and type 2 diabetes. New England J. Med. 363:12 (2010), 1146–1155, 10.1056/NEJMoa1005109.
8. Szczech, L.A., Barnhart, H.X., Inrig, J.K., Reddan, D.N., Sapp, S., Califf, R.M., Patel, U.D., Singh, A.K., Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int. 74:6 (2008), 791–798, 10.1038/ki.2008.29510.1038/ki.2008.295.
9. Fukui, K., Shinozaki, Y., Kobayashi, H., Deai, K., Yoshiuchi, H., Matsui, T., Matsuo, A., Matsushita, M., Tanaka, T., Nangaku, M., JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-alpha protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. Eur. J. Pharmacol., 859, 2019, 172532, 10.1016/j.ejphar.2019.172532.
10. Drueke, T., Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England J. Med. 355 (2006), 2071–2084, 10.1056/NEJMoa062276.
11. Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson, M., Reddan, D., Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355:20 (2006), 2085–2098, 10.1056/NEJMoa065485.
12. Majmundar, A.J., Wong, W.J., Simon, M.C., Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40:2 (2010), 294–309, 10.1016/j.molcel.2010.09.022.
13. Caldwell, D.M., Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ Br. Med. J. 331:7521 (2005), 897–900, 10.1136/bmj.331.7521.897.
14. Chaimani, A., Caldwell, D.M., Li, T., Higgins, J.P., Salanti, G., Additional considerations are required when preparing a protocol for a systematic review with multiple interventions. J. Clin. Epidemiol. 83 (2017), 65–74, 10.1016/j.jclinepi.2016.11.015.
15. Julian Higgins, Sally Green, Cochrane handbook for systematic reviews of interventions, The Cochrane Collaboration.
16. Salanti, G., Giovane, C.D., Chaimani, A., Caldwell, D.M., Higgins, J.P.T., Evaluating the quality of evidence from a network meta-analysis. PLoS One, 9(7), 2014, 10.1371/journal.pone.0099682.
17. Greco, T., Edefonti, V., Biondi-Zoccai, G., Decarli, A., Gasparini, M., Zangrillo, A., Landoni, G., A multilevel approach to network meta-analysis within a frequentist framework. Contemp. Clin. Trials 42 (2015), 51–59, 10.1016/j.cct.2015.03.005 (Complete).
18. Salanti, G., Ades, A.E., Ioannidis, J.P.A., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64:2 (2011), 163–171, 10.1016/j.jclinepi.2010.03.016.
19. Higgins, J.P., Jackson, D., Barrett, J.K., Lu, G., Ades, A.E., White, I.R., Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res. Synth. Methods 3:2 (2012), 98–110 https://doi.org/98-110.10.1002/jrsm.1044.
20. Anna, C., Higgins, Julian P.T., Dimitris, M., Panagiota, S., Georgia, S., Benjamin, H., Graphical tools for network meta-analysis in STATA. PLoS One, 8(10), 2013, e76654, 10.1371/journal.pone.0076654.
21. Roger, S.D., Jassal, S.V., Woodward, M.C., Soroka, S., McMahon, L.P., A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE. Int. Urol. Nephrol. 46:2 (2014), 469–475 https://doi.org/469-475.10.1007/s11255-013-0512-1.
22. Pergola, P.E., Spinowitz, B.S., Hartman, C.S., Maroni, B.J., Haase, V.H., Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 90:5 (2016), 1115–1122 https://doi.org/1115-1122.10.1016/j.kint.2016.07.019.
23. Holdstock, L., Meadowcroft, A.M., Maier, R., Johnson, B.M., Jones, D., Rastogi, A., Zeig, S., Lepore, J.J., Cobitz, A.R., Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J. Am. Soc. Nephrol. 27:4 (2016), 1234–1244 https://doi.org/1234-1244.10.1681/ASN.2014111139.
24. Brigandi, R.A., Johnson, B., Oei, C., Westerman, M., Olbina, G., de Zoysa, J., Roger, S.D., Sahay, M., Cross, N., McMahon, L., Guptha, V., Smolyarchuk, E.A., Singh, N., Russ, S.F., Kumar, S., Borsukov, A.V., Marasaev, V.V., Prasad, G., Timokhovskaya, G.Y., Kolmakova, E.V., Dobronravov, V.A., Zakharova, E.V., Abraham, G., Packham, D., Zateyshchikov, D.A., Arutyunov, G.P., Volgina, G.V., Lipatov, K.S., Perlin, D.V., Cooper, B., Kumar Saha, T., Zagrebelnaya, O.A., Mehta, K.S., Koziolova, N.A., Fassett, R., Alexeeva, N.P., Lysenko, L.V., A novel hypoxia-inducible factor−Prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-Day, phase 2A randomized trial. Am. J. Kidney Dis. 67:6 (2016), 861–871 https://doi.org/861-871.10.1053/j.ajkd.2015.11.021.
25. Macdougall, I.C., Akizawa, T., Berns, J.S., Bernhardt, T., Krueger, T., Effects of molidustat in the treatment of anemia in CKD. Clin. J. Am. Soc. Nephrol. 14:1 (2019), 28–39, 10.2215/CJN.02510218.
26. Mc Causland, F.R., Claggett, B., Burdmann, E.A., Chertow, G.M., Cooper, M.E., Eckardt, K., Ivanovich, P., Levey, A.S., Lewis, E.F., McGill, J.B., McMurray, J.J.V., Parfrey, P., Parving, H., Remuzzi, G., Singh, A.K., Solomon, S.D., Toto, R.D., Pfeffer, M.A., Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). Am. J. Kidney Dis. 73:3 (2019), 309–315, 10.1053/j.ajkd.2018.10.006.
27. Holdstock, L., Cizman, B., Meadowcroft, A.M., Biswas, N., Johnson, B.M., Jones, D., Kim, S.G., Zeig, S., Lepore, J.J., Cobitz, A.R., Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin. Kidney J. 12:1 (2019), 129–138, 10.1093/ckj/sfy013.
28. Parmar, D.V., Kansagra, K.A., Patel, J.C., Joshi, S.N., Sharma, N.S., Shelat, A.D., Patel, N.B., Nakrani, V.B., Shaikh, F.A., Patel, H.V., Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am. J. Nephrol. 49:6 (2019), 470–478, 10.1159/000500232.
29. Akizawa, T., Iwasaki, M., Otsuka, T., Reusch, M., Misumi, T., Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Adv. Ther. 36:6 (2019), 1438–1454, 10.1007/s12325-019-00943-4.
30. Macdougall, Iain C., Safety and efficacy of molidustat in erythropoiesis stimulating agents (esa) pre-treated anaemic patients with chronic kidney safety and efficacy of molidustat in erythropoiesis stimulating agents (esa) pre-treated anaemic patients with chronic kidney disease not on dialysis (ckd-nd). Nephrol. Dial. Transplant., 31(Supplement 1), 2016 https://doi.org/i193-i199.10.1093/ndt/gfw166.1.
31. Martin, E.R., Smith, M.T., Maroni, B.J., Zuraw, Q.C., DeGoma, E.M., Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am. J. Nephrol. 45:5 (2017), 380–388, 10.1159/000464476.
32. Chen, N., Chen, J., Hao, L., Hao, C., Peng, X., Lin, H., Yin, A., Tao, Y., Liang, X., Liu, Z., Liu, B., Liu, C., Xing, C., Luo, L., Zuo, L., Liao, Y., Leong, R., Wang, C., Neff, T., Szczech, L., Yu, K.P., Roxadustat for anemia in patients with kidney disease not receiving dialysis. N. Engl. J. Med. 381:11 (2019), 1001–1010, 10.1056/NEJMoa1813599.
33. Besarab, A., Provenzano, R., Hertel, J., Zabaneh, R., Klaus, S.J., Lee, T., Leong, R., Hemmerich, S., Yu, K.P., Neff, T.B., Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol. Dial. Transplant. 30:10 (2015), 1665–1673 https://doi.org/1665-1673.10.1093/ndt/gfv302.
34. Akizawa, T., Nangaku, M., Yamaguchi, T., Arai, M., Koretomo, R., Matsui, A., Hirakata, H., Placebo-Controlled, A., Randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial. Am. J. Nephrol. 49:2 (2019), 165–174, 10.1159/000496929.
35. Chen, N., Qian, J., Chen, J., Yu, X., Mei, C., Hao, C., Jiang, G., Lin, H., Zhang, X., Zuo, L., He, Q., Fu, P., Li, X., Ni, D., Hemmerich, S., Liu, C., Szczech, L., Besarab, A., Neff, T.B., Peony Yu, K., Valone, F.H., Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol. Dial. Transplant. 32:8 (2017), 1373–1386 https://doi.org/1373-1386.10.1093/ndt/gfx011.
36. Palazzuoli, A., Quatrini, I., Calabrò, A., Antonelli, G., Caputo, M., Campagna, M.S., Franci, B., Nuti, R., Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clin. Exp. Med. 11:1 (2011), 43–48, 10.1007/s10238-010-0100-y.
37. Kleinman, K.S., Schweitzer, S.U., Perdue, S.T., Bleifer, K.H., Abels, R.I., The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am. J. Kidney Dis. 15:6 (1989), 486–495, 10.1016/S0272-6386(89)80149-0.
38. Palazzuoli, A., Silverberg, D.S., Iovine, F., Calabrò, A., Campagna, M.S., Gallotta, M., Nuti, R., Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am. Heart J., 154(4), 2007, 645 e9-645.e15 https://doi.org/645-649.10.1016/j.ahj.2007.07.022.
39. Locatelli, F., Olivares, J., Walker, R., Wilkie, M., Jenkins, B., Dewey, C., Gray, S.J., European, A.N.S.G., Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 60:2 (2001), 741–747, 10.1046/j.1523-1755.2001.060002741.x.
40. Jjv, M.M., Parfrey, P.S., Al, E., KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2:4 (2012), 279–335.
41. Koury, M.J., Haase, V.H., Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat. Rev. Nephrol. 11:7 (2015), 394–410, 10.1038/nrneph.2015.82.
42. Moslehi, J., Minamishima, Y.A., Shi, J., Neuberg, D., Charytan, D.M., Padera, R.F., Signoretti, S., Liao, R., Kaelin, W.G., Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 122:10 (2010), 1004–1016, 10.1161/CIRCULATIONAHA.109.922427.
43. Percy, M.J., Furlow, P.W., Lucas, G.S., Li, X., Lappin, T.R.J., McMullin, M.F., Lee, F.S., A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 358:2 (2008), 162–168.
44. Flamme, I., Oehme, F., Ellinghaus, P., Jeske, M., Keldenich, J.R., Thuss, U., Bussolati, B., Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One, 9(11), 2014, e111838, 10.1371/journal.pone.0111838.
45. Mastrogiannaki, M., Matak, P., Keith, B., Simon, M.C., Peyssonnaux, C., HIF-2α, but not HIF-1α, promotes iron absorption in mice. J. Clin. Invest. 119:5 (2009), 1159–1166, 10.1172/JCI38499.
46. Hui, D., Cai-Zhen, Y., Honglian, S., Ya-Shuo, Z., Shi-Yang, C., Peng, Y., Wen-Shuang, W., Chen-Yang, Z., Yan-Zhong, C., Xiang-Lin, D., Hepcidin is involved in iron regulation in the ischemic brain. PLoS One, 6(9), 2011, e25324, 10.1371/journal.pone.0025324.
47. Yan, L., Colandrea, V.J., Hale, J.J., Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin. Ther. Pat. 20:9 (2010), 1219–1245, 10.1517/13543776.2010.510836.
48. Rolfs, A., Kvietikova, I., Gassmann, M., Wenger, R.H., Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J. Biol. Chem. 272:32 (1997), 20055–20062, 10.1074/jbc.272.32.20055.
49. Laura, B., Lorenza, T., Gaetano, C., HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res. 27:21 (1999), 4223–4227, 10.1093/nar/27.21.4223.
50. Hentze, M.W., Muckenthaler, M.U., Galy, B., Camaschella, C., Two to tango: regulation of mammalian iron metabolism. Physiol. Rev. 142:1 (2010), 24–38, 10.1016/j.cell.2010.06.028.
51. Ganz, T., Systemic iron homeostasis. Physiol. Rev. 93:4 (2013), 1721–1741, 10.1152/physrev.00008.2013.
52. Ueda, N., Takasawa, K., Role of hepcidin-25 in chronic kidney disease: anemia and beyond. Curr. Med. Chem. 24:14 (2017), 1417–1452, 10.2174/0929867324666170316120538.
53. Liu, J., Zhang, A., Hayden, J.C., Bhagavathula, A.S., Alshehhi, F., Rinaldi, G., Kontogiannis, V., Rahmani, J., Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: a systematic review and meta-analysis. Pharmacol. Res., 155, 2020, 104747, 10.1016/j.phrs.2020.104747.
54. Xie, D., Wang, J., Wu, X., Li, M., Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis. Int. Urol. Nephrol. 50:12 (2018), 2201–2206, 10.1007/s11255-018-1940-8.
55. Zhong, H., Zhou, T., Li, H., Zhong, Z., The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Des Dev Ther. 12 (2018), 3003–3011, 10.2147/DDDT.S175887.
56. Wilhelm-Leen, E.R., Winkelmayer, W.C., Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am. J. Kidney Dis. 66:1 (2015), 69–74, 10.1053/j.ajkd.2014.12.012.
57. Kalaitzidis, R.G., Elisaf, M.S., The role of statins in chronic kidney disease. Am. J. Nephrol. 34:3 (2011), 195–202 https://doi.org/195-202.10.1159/000330355.
58. Kassimatis, T.I., Goldsmith, D.J., Statins in chronic kidney disease and kidney transplantation. Pharmacol. Res. 88 (2014), 187–199 https://doi.org/62-73.10.1016/j.phrs.2014.06.011.
59. Gupta, N., Wish, J.B., Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am. J. Kidney Dis., 2017, S1611681679.
60. Pfeffer, M.A., Burdmann, E.A., Chen, C., Cooper, M.E., de Zeeuw, D., Eckardt, K., Feyzi, J.M., Ivanovich, P., Kewalramani, R., Levey, A.S., Lewis, E.F., McGill, J.B., McMurray, J.J.V., Parfrey, P., Parving, H., Remuzzi, G., Singh, A.K., Solomon, S.D., Toto, R., TREAT, I., A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361:21 (2009), 2019–2032 https://doi.org/2019-2032.10.1056/NEJMoa0907845.